Zenyaku Ends Japan Alliance With Anthera
This article was originally published in Scrip
Executive Summary
US firm Anthera Pharmaceuticals Inc.'s development partner in Japan for autoimmune disorder drug blisibimod has served a termination notice for the late 2014 deal, but the US firm says the impact could in fact be positive.